Skip to main content

Table 6 Risk of LLA in current GLP1-RA use compared to current SU use, stratified by concomitant antihypertensive use, and history of peripheral arterial disease

From: The use of sodium-glucose co-transporter-2 inhibitors or glucagon-like peptide-1 receptor agonists versus sulfonylureas and the risk of lower limb amputations: a nation-wide cohort study

 

Number of LLAs (N = 564)

IR (/1000 PY

Age/sex adjusted HR (95%CI)

Fully adjusted HR (95%CI)

p-value Wald test

Current SU use

54

2.14

Reference

  

Current GLP1-RA use

55

1.51

0.88 (0.60–1.29)

0.57 (0.39–0.84)a

 

 By concomitant antihypertensive use in the previous 3 months

  Diuretics

   Yes

27

1.81

0.96 (0.60–1.52)

0.55 (0.34–0.88)b

0.74

   No

28

1.31

0.82 (0.52–1.30)

0.60 (0.38–0.96)b

 

 Drugs acting on RAAS

   Yes

34

1.64

0.88 (0.57–1.35)

0.57 (0.36–0.88)c

0.98

   No

21

1.35

0.89 (0.53–1.47)

0.57 (0.34–0.95)c

 

  By history of PAD

   Yes

17

9.86

4.05 (2.35–7.00)

0.94 (0.54–1.65)d

0.04

   No

38

1.10

0.65 (0.43–0.99)

0.51 (0.33–0.77)d

 
  1. The models have also been adjusted for current DPP4-I use (149 LLAs), current combined use (90 LLAs), current other NIGLD use (59 LLAs), current SGLT2-I use (36 LLAs) and past NIGLD use (121 LLAs) (not shown)
  2. LLA lower limb amputation, IR incidence rate, PY person years, HR hazard ratio, CI confidence interval, NIGLD non-insulin glucose lowering drug, SU sulfonylurea, DPP4-I dipeptidyl peptidase-4 inhibitor, GLP1-RA glucagon-like peptide-1 receptor agonist
  3. aAdjusted for age; sex; diabetes duration; income category; immigrant status; education; history of diabetic foot ulcer, neuropathy, atherosclerosis, peripheral arterial disease, hypertension, retinopathy, heart failure, hyperlipidaemia, ischaemic heart disease, osteomyelitis, renal disease, pulmonary heart disease, or bacterial foot infection; and the use of loop diuretics, antithrombotic agents, potassium sparing diuretics, beta blockers, lipid lowering drugs, angiotensin receptor blockers, digoxin, angiotensin converting enzyme blockers, or calcium channel blockers in the 6 months before the start of the exposure interval
  4. bAdjusted for age; sex; diabetes duration; income category; immigrant status; education; history of diabetic foot ulcer, neuropathy, atherosclerosis, peripheral arterial disease, hypertension, retinopathy, heart failure, hyperlipidaemia, ischaemic heart disease, osteomyelitis, renal disease, pulmonary heart disease, or bacterial foot infection; and the use of antithrombotic agents, beta blockers, lipid lowering drugs, angiotensin receptor blockers, digoxin, angiotensin converting enzyme blockers, or calcium channel blockers in the 6 months before the start of the exposure interval
  5. cAdjusted for age; sex; diabetes duration; income category; immigrant status; education; history of diabetic foot ulcer, neuropathy, atherosclerosis, peripheral arterial disease, hypertension, retinopathy, heart failure, hyperlipidaemia, ischaemic heart disease, osteomyelitis, renal disease, pulmonary heart disease, or bacterial foot infection; and the use of loop diuretics, antithrombotic agents, potassium sparing diuretics, beta blockers, lipid lowering drugs, digoxin, or calcium channel blockers in the 6 months before the start of the exposure interval
  6. dAdjusted for age; sex; diabetes duration; income category; immigrant status; education; history of diabetic foot ulcer, neuropathy, atherosclerosis, hypertension, retinopathy, heart failure, hyperlipidaemia, ischaemic heart disease, osteomyelitis, renal disease, pulmonary heart disease, or bacterial foot infection; and the use of loop diuretics, antithrombotic agents, potassium sparing diuretics, beta blockers, lipid lowering drugs, angiotensin receptor blockers, digoxin, angiotensin converting enzyme blockers, or calcium channel blockers in the 6 months before the start of the exposure interval
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840